Comparative aluminium mobilizing actions of deferoxamine and four 3-hydroxypyrid-4-ones in aluminium-loaded rats

Toxicology

Volumn 130, Issue 2-3, 1998, Pages 175-181

  Gómez, Mercedes ^a   Esparza, Jose L ^a   Domingo, Jose L ^a   Singh, Pramod K ^b   Jones, Mark M ^b  

^a UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

3 Hidroxypyridin 4 ones; Aluminium distribution; Aluminium excretion; Deferoxamine; Rats

Indexed keywords

3 HYDROXY 4 PYRIDONE DERIVATIVE; ALUMINUM; ALUMINUM NITRATE; DEFEROXAMINE; ALUMINUM DERIVATIVE; CHELATING AGENT; NITRATE; PYRIDONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE; BRAIN; CHELATION; CONTROLLED STUDY; INTOXICATION; KIDNEY; LIVER; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; SPLEEN; ANIMAL; CHEMISTRY; COMPARATIVE STUDY; SPRAGUE DAWLEY RAT; TISSUE DISTRIBUTION; URINE;

ALUMINUM; ALUMINUM COMPOUNDS; ANIMALS; CHELATING AGENTS; DEFEROXAMINE; MALE; NITRATES; PYRIDONES; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 0032529830     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-483X(98)00109-7     Document Type: Article

References (41)

1. Ackrill, P., Day, J.P., 1993. The use of desferrioxamine in dialysis-associated aluminium disease. In: Bourke, E., Mallick, N.P., Pollak, V.E. (Eds.), Moving Points in Nephrology, Contrib. Nephrol., vol. 102. Karger, Basel, pp. 125-134.
2. Allen D.D., Orvig C., Yokel R.A. Pharmacokinetics of aluminium 3-hydroxypyridin-4-one complexes: implications for aluminium redistribution subsequent to chelation therapy. Toxicology. 92:1994;193-202.
3. Bast-Pettersen R., Drablos P.R., Goffeng L.O., Thomasssen Y., Torres C.G. Neuropsychological deficit among elderly workers in aluminium production. Am. J. Ind. Med. 25:1994;649-662.
4. Cherroret G., Desor D., Hutin M.F., Burnel D., Capolaghi B., Lehr P.R. Effects of aluminium chloride on normal and uremic adult male rats. Tissue distribution, brain choline acetyltransferase activity and some biological variables. Biol. Trace Elem. Res. 54:1996;43-53.
5. Domingo J.L. The use of chelating agents in the treatment of aluminium overload. Clin. Toxicol. 27:1989;355-367.
6. Domingo J.L. Adverse effects of aluminium-chelating compounds for clinical use. Adverse Drug React. Toxicol. Rev. 15:1996;145-165.
7. Domingo J.L., Gomez M., Llobet J.M., Corbella J. Comparative effects of several chelating agents on the toxicity, distribution, and excretion of aluminium. Hum. Toxicol. 7:1988a;259-262.
8. Domingo J.L., Gomez M., Llobet J.M., Corbella J. Citric, malic, and succinic acids as possible alternatives to aluminium toxicity. Clin. Toxicol. 26:1988b;67-69.
9. Elorriaga R., Fernández-Martin J.L., Menéndez-Fraga P. et al. Aluminium removal: short- and long-term preliminary results with L1 in rats. Drugs Today. 28:1992;177-182.
10. Fernández-Martin J.L., Menéndez-Fraga P., Canteros M.A., Diaz-Lopez J.B., Cannata-Andia J.B. Binding of aluminium to plasma proteins: comparative effect of desferrioxamine and deferiprone (L1). Clin. Chim. Acta. 230:1994;137-145.
11. Flaten T.P., Alfrey A.C., Birchall J.D., Savory J., Yokel R.A. Status and future concerns of clinical and environmental aluminium toxicology. J. Toxicol. Environ. Health. 48:1996;527-541.
12. Fredenburg A.M., Sethi R.K., Allen D.D., Yokel R.A. The pharmacokinetics and blood-brain barrier permeation of the chelators 1,2-dimethyl-, 1,2-diethyl-, and 1-[ethan-1′ol]-2-methyl-3-hydroxypyrid-4-one in the rat. Toxicology. 108:1996;191-199.
13. Gale G.R., Lichtenberg W.H., Smith A.B., Singh P.K., Campbell R.A., Jones M.M. Comparative iron mobilizing actions of deferoxamine, 1,2-dimethyl-3-hydroxypyrid-4-one and pyridoxal isonicotinoyl hydrazone in iron hydroxamate-loaded mice. Res. Commun. Chem. Pathol. Pharmacol. 73:1991;299-313.
14. Garruto R.M. Pacific paradigms of environmentally-induced neurological disorders: clinical, epidemiological, and molecular perspectives. Neurotoxicology. 12:1991;347-378.
15. Gómez M., Domingo J.L., del Castillo D., Llobet J.M., Corbella J. Comparative aluminium mobilizing actions of several chelators in aluminium-loaded uraemic rats. Hum. Exp. Toxicol. 13:1994a;135-139.
16. Gómez M., Llobet J.M., Santafé M., Domingo J.L., Corbella J. A short-term toxicity study of L1, a potential aluminium and iron chelator, in normal rats. Collery P.H., Poirier L.A., Littlefield N.A., Etienne J.C. Metal Ions in Biology and Medicine. 3:1994b;85-89 John Libbey Eurotext, Paris.
17. Gómez M., Domingo J.L., del Castillo D., Llobet J.M., Corbella J. Four-week oral toxicity study of 1,2-dimethyl-3-hydroxypyridin-4-one (L1) in uremic rats. Vet. Hum. Toxicol. 37:1995;346-348.
18. Gómez M., Sanchez D.J., Llobet J.M., Corbella J., Domingo J.L. The effect of age on aluminium retention in rats. Toxicology. 116:1997;1-8.
19. Gómez M., Esparza J.L., Domingo J.L., Corbella J., Singh P.K., Jones M.M. Aluminium distribution and excretion: a comparative study of a number of chelating agents in rats. Pharmacol. Toxicol. 82:1998;295-300.
20. Good P.F., Olanow C.W., Perl D.P. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminium in Parkinson's disease: a LAMMA study. Brain Res. 593:1992;343-346.
21. Graff L., Muller G., Burnel D. In vitro and in vivo comparative studies of chelation of aluminium by some polyaminocarboxylic acids. Res. Commun. Chem. Pathol. Pharmacol. 88:1995a;271-292.
22. Graff L., Muller G., Burnel D. In vitro and in vivo evaluation of potential aluminium chelators. Vet. Hum. Toxicol. 37:1995b;455-461.
23. Jablonski G., Klem K.H., Danielsen C.Ch., Mosekilde L., Gordelazde J.O. Aluminium-induced bone disease in uremic rats: effect of deferoxamine. Biosci. Reports. 16:1996;49-63.
24. Kontoghiorghes G.J. Future of oral iron chelator deferiprone (L1) (letter). Lancet. 341:1993;1480-1481.
25. Kontoghiorghes G.J. Comparative efficacy and toxicity of desferrioxamine, deferiprone, and other iron and aluminium chelating drugs. Toxicol. Lett. 80:1995;1-18.
26. Llobet J.M., Domingo J.L., Gómez M., Tomas J.M., Corbella J. Acute toxicity studies of aluminium compounds: antidotal efficacy of several chelating agents. Pharmacol. Toxicol. 60:1987;280-283.
27. McCarthy J.T., Milliner D.S., Johnson W.J. Clinical experience withdesferrioxamine in dialysis patients with aluminium toxicity. Q. J. Med. 275:1990;257-276.
28. McLachlan D.R.C., Dalton A.J., Kruck T.P.A. et al. Intramuscular desferrioxmine in patients with Alzheimer's disease. Lancet. 337:1991;1304-1308.
29. McLachlan D.R.C. Aluminium and the risk for Alzheimer's disease. Environmetrics. 6:1995;233-275.
30. Molenda J.J., Jones M.M., Cecil K.M., Basinger M.A. Structure/activity relationships affecting the ability of monoanionic 3-hydroxypyrid-4-ones to mobilize iron. Chem. Res. Toxicol. 7:1994;815-822.
31. Nieboer E., Gibson B.L., Oxman A.D., Kramer J.R. Health effects of aluminium: a critical review with emphasis on aluminium in drinking water. Environ. Rev. 3:1995;29-81.
32. Pfannkuch F., Bentley P., Schnebli H.P. Future of oral iron chelator deferiprone (L1) (letter). Lancet. 341:1993;1480.
33. Porter J.B., Huehns E.R., Hider R.C. The development of iron chelating drugs. Baillieres. Clin. Haematol. 2:1989;257-292.
34. Singh P.K., Jones M.M., Lane J.E. et al. Synthesis and in vitro trypanocidal activity of some novel iron chelating agents Arzneim-Forsch. Drug Res. 47:1997;311-315.
35. Sutherland J.E., Radzanowski G.M., Greger J.L. Bile is an important route of elimination of ingested aluminium by conscious male Sprague-Dawley rats. Toxicology. 109:1996;101-109.
36. White D.M., Longstreth W.T., Rosentock L. et al. Neurologic syndrome in 25 workers from an aluminium smelting plant. Arch. Intern. Med. 152:1992;1443-1448.
37. Yokel R.A. Aluminium chelation: chemistry, clinical, and experimental studies and the search for alternatives to desferrioxamine. J. Toxicol. Environ. Health. 41:1994;131-174.
38. Yokel R.A. Aluminium chelation by 3-hydroxypyridin-4-ones in the rat demonstrated by microdialysis. Biol. Trace Elem. Res. 53:1996;193-203.
39. Yokel R.A., Datta A.K., Jackson E.G. Evaluation of potential aluminium chelators in vitro by aluminium solubilization ability, aluminium mobilization from transferrin and the octanol/aqueous distribution of the chelators and their complexes with aluminium. J. Pharmacol. Exp. Ther. 257:1991;100-106.
40. Yokel R.A., Lidums V., Ungerstedt U. Aluminium mobilization by desferrioxamine assessed by microdialysis of the blood, liver, and brain. Toxicology. 66:1991;313-324.
41. Yokel R.A., Ackrill P., Burgess E. et al. Prevention and treatment of aluminium toxicity including chelation therapy: status and research needs. J. Toxicol. Environ. Health. 48:1996;667-683.